April 29, 2021 10:44 AM EDTUpdated April 30, 04:03 PM
R&D

Cara touts sub­group in failed atopic der­mati­tis tri­al, but stock craters

Jason Mast

Editor

Cara Ther­a­peu­tics will join the grow­ing list of biotech to launch a Phase III de­spite fail­ing Phase II.

The itch-fo­cused com­pa­ny an­nounced Thurs­day that its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times